Recent submissions

  • RAD51B in Familial Breast Cancer. 

    Pelttari, LM; Khan, S; Vuorela, M; Kiiski, JI; Vilske, S; Nevanlinna, V; Ranta, S; Schleutker, J; Winqvist, R; Kallioniemi, A; Dörk, T; Bogdanova, NV; Figueroa, J; Pharoah, PD; Schmidt, MK; Dunning, AM; García-Closas, M; Bolla, MK; Dennis, J; Michailidou, K; Wang, Q; Hopper, JL; Southey, MC; Rosenberg, EH; Fasching, PA; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Surowy, H; Guénel, P; Truong, T; Bojesen, SE; Nordestgaard, BG; Benitez, J; González-Neira, A; Neuhausen, SL; Anton-Culver, H; Brenner, H; Arndt, V; Meindl, A; Schmutzler, RK; Brauch, H; Brüning, T; Lindblom, A; Margolin, S; Mannermaa, A; Hartikainen, JM; Chenevix-Trench, G; Van Dyck, L; Janssen, H; Chang-Claude, J; Rudolph, A; Radice, P; Peterlongo, P; Hallberg, E; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Schumacher, F; Simard, J; Dumont, M; Kristensen, V; Borresen-Dale, AL; Zheng, W; Beeghly-Fadiel, A; Grip, M; Andrulis, IL; Glendon, G; Devilee, P; Seynaeve, C; Hooning, MJ; Collée, M; Cox, A; Cross, SS; Shah, M; Luben, RN; Hamann, U; Torres, D; Jakubowska, A; Lubinski, J; Couch, FJ; Yannoukakos, D; Orr, N; Swerdlow, A; Darabi, H; Li, J; Czene, K; Hall, P; Easton, DF; Mattson, J; Blomqvist, C; Aittomäki, K; Nevanlinna, H (2016-01)
    Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study ...
  • Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. 

    Milne, RL; Kuchenbaecker, KB; Michailidou, K; Beesley, J; Kar, S; Lindström, S; Hui, S; Lemaçon, A; Soucy, P; Dennis, J; Jiang, X; Rostamianfar, A; Finucane, H; Bolla, MK; McGuffog, L; Wang, Q; Aalfs, CM; ABCTB Investigators; Adams, M; Adlard, J; Agata, S; Ahmed, S; Ahsan, H; Aittomäki, K; Al-Ejeh, F; Allen, J; Ambrosone, CB; Amos, CI; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Arnold, N; Aronson, KJ; Auber, B; Auer, PL; Ausems, MGEM; Azzollini, J; Bacot, F; Balmaña, J; Barile, M; Barjhoux, L; Barkardottir, RB; Barrdahl, M; Barnes, D; Barrowdale, D; Baynes, C; Beckmann, MW; Benitez, J; Bermisheva, M; Bernstein, L; Bignon, Y-J; Blazer, KR; Blok, MJ; Blomqvist, C; Blot, W; Bobolis, K; Boeckx, B; Bogdanova, NV; Bojesen, A; Bojesen, SE; Bonanni, B; Børresen-Dale, A-L; Bozsik, A; Bradbury, AR; Brand, JS; Brauch, H; Brenner, H; Bressac-de Paillerets, B; Brewer, C; Brinton, L; Broberg, P; Brooks-Wilson, A; Brunet, J; Brüning, T; Burwinkel, B; Buys, SS; Byun, J; Cai, Q; Caldés, T; Caligo, MA; Campbell, I; Canzian, F; Caron, O; Carracedo, A; Carter, BD; Castelao, JE; Castera, L; Caux-Moncoutier, V; Chan, SB; Chang-Claude, J; Chanock, SJ; Chen, X; Cheng, T-YD; Chiquette, J; Christiansen, H; Claes, KBM; Clarke, CL; Conner, T; Conroy, DM; Cook, J; Cordina-Duverger, E; Cornelissen, S; Coupier, I; Cox, A; Cox, DG; Cross, SS; Cuk, K; Cunningham, JM; Czene, K; Daly, MB; Damiola, F; Darabi, H; Davidson, R; De Leeneer, K; Devilee, P; Dicks, E; Diez, O; Ding, YC; Ditsch, N; Doheny, KF; Domchek, SM; Dorfling, CM; Dörk, T; Dos-Santos-Silva, I; Dubois, S; Dugué, P-A; Dumont, M; Dunning, AM; Durcan, L; Dwek, M; Dworniczak, B; Eccles, D; Eeles, R; Ehrencrona, H; Eilber, U; Ejlertsen, B; Ekici, AB; Eliassen, AH; EMBRACE; Engel, C; Eriksson, M; Fachal, L; Faivre, L; Fasching, PA; Faust, U; Figueroa, J; Flesch-Janys, D; Fletcher, O; Flyger, H; Foulkes, WD; Friedman, E; Fritschi, L; Frost, D; Gabrielson, M; Gaddam, P; Gammon, MD; Ganz, PA; Gapstur, SM; Garber, J; Garcia-Barberan, V; García-Sáenz, JA; Gaudet, MM; Gauthier-Villars, M; Gehrig, A; GEMO Study Collaborators; Georgoulias, V; Gerdes, A-M; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Goodfellow, P; Greene, MH; Alnæs, GIG; Grip, M; Gronwald, J; Grundy, A; Gschwantler-Kaulich, D; Guénel, P; Guo, Q; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hallberg, E; Hamann, U; Hamel, N; Hankinson, S; Hansen, TVO; Harrington, P; Hart, SN; Hartikainen, JM; Healey, CS; HEBON; Hein, A; Helbig, S; Henderson, A; Heyworth, J; Hicks, B; Hillemanns, P; Hodgson, S; Hogervorst, FB; Hollestelle, A; Hooning, MJ; Hoover, B; Hopper, JL; Hu, C; Huang, G; Hulick, PJ; Humphreys, K; Hunter, DJ; Imyanitov, EN; Isaacs, C; Iwasaki, M; Izatt, L; Jakubowska, A; James, P; Janavicius, R; Janni, W; Jensen, UB; John, EM; Johnson, N; Jones, K; Jones, M; Jukkola-Vuorinen, A; Kaaks, R; Kabisch, M; Kaczmarek, K; Kang, D; Kast, K; kConFab/AOCS Investigators; Keeman, R; Kerin, MJ; Kets, CM; Keupers, M; Khan, S; Khusnutdinova, E; Kiiski, JI; Kim, S-W; Knight, JA; Konstantopoulou, I; Kosma, V-M; Kristensen, VN; Kruse, TA; Kwong, A; Lænkholm, A-V; Laitman, Y; Lalloo, F; Lambrechts, D; Landsman, K; Lasset, C; Lazaro, C; Le Marchand, L; Lecarpentier, J; Lee, A; Lee, E; Lee, JW; Lee, MH; Lejbkowicz, F; Lesueur, F; Li, J; Lilyquist, J; Lincoln, A; Lindblom, A; Lissowska, J; Lo, W-Y; Loibl, S; Long, J; Loud, JT; Lubinski, J; Luccarini, C; Lush, M; MacInnis, RJ; Maishman, T; Makalic, E; Kostovska, IM; Malone, KE; Manoukian, S; Manson, JE; Margolin, S; Martens, JWM; Martinez, ME; Matsuo, K; Mavroudis, D; Mazoyer, S; McLean, C; Meijers-Heijboer, H; Menéndez, P; Meyer, J; Miao, H; Miller, A; Miller, N; Mitchell, G; Montagna, M; Muir, K; Mulligan, AM; Mulot, C; Nadesan, S; Nathanson, KL; NBSC Collaborators; Neuhausen, SL; Nevanlinna, H; Nevelsteen, I; Niederacher, D; Nielsen, SF; Nordestgaard, BG; Norman, A; Nussbaum, RL; Olah, E; Olopade, OI; Olson, JE; Olswold, C; Ong, K-R; Oosterwijk, JC; Orr, N; Osorio, A; Pankratz, VS; Papi, L; Park-Simon, T-W; Paulsson-Karlsson, Y; Lloyd, R; Pedersen, IS; Peissel, B; Peixoto, A; Perez, JIA; Peterlongo, P; Peto, J; Pfeiler, G; Phelan, CM; Pinchev, M; Plaseska-Karanfilska, D; Poppe, B; Porteous, ME; Prentice, R; Presneau, N; Prokofieva, D; Pugh, E; Pujana, MA; Pylkäs, K; Rack, B; Radice, P; Rahman, N; Rantala, J; Rappaport-Fuerhauser, C; Rennert, G; Rennert, HS; Rhenius, V; Rhiem, K; Richardson, A; Rodriguez, GC; Romero, A; Romm, J; Rookus, MA; Rudolph, A; Ruediger, T; Saloustros, E; Sanders, J; Sandler, DP; Sangrajrang, S; Sawyer, EJ; Schmidt, DF; Schoemaker, MJ; Schumacher, F; Schürmann, P; Schwentner, L; Scott, C; Scott, RJ; Seal, S; Senter, L; Seynaeve, C; Shah, M; Sharma, P; Shen, C-Y; Sheng, X; Shimelis, H; Shrubsole, MJ; Shu, X-O; Side, LE; Singer, CF; Sohn, C; Southey, MC; Spinelli, JJ; Spurdle, AB; Stegmaier, C; Stoppa-Lyonnet, D; Sukiennicki, G; Surowy, H; Sutter, C; Swerdlow, A; Szabo, CI; Tamimi, RM; Tan, YY; Taylor, JA; Tejada, M-I; Tengström, M; Teo, SH; Terry, MB; Tessier, DC; Teulé, A; Thöne, K; Thull, DL; Tibiletti, MG; Tihomirova, L; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Tong, L; Torres, D; Tranchant, M; Truong, T; Tucker, K; Tung, N; Tyrer, J; Ulmer, H-U; Vachon, C; van Asperen, CJ; Van Den Berg, D; van den Ouweland, AMW; van Rensburg, EJ; Varesco, L; Varon-Mateeva, R; Vega, A; Viel, A; Vijai, J; Vincent, D; Vollenweider, J; Walker, L; Wang, Z; Wang-Gohrke, S; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wesseling, J; Whittemore, AS; Wijnen, JT; Willett, W; Winqvist, R; Wolk, A; Wu, AH; Xia, L; Yang, XR; Yannoukakos, D; Zaffaroni, D; Zheng, W; Zhu, B; Ziogas, A; Ziv, E; Zorn, KK; Gago-Dominguez, M; Mannermaa, A; Olsson, H; Teixeira, MR; Stone, J; Offit, K; Ottini, L; Park, SK; Thomassen, M; Hall, P; Meindl, A; Schmutzler, RK; Droit, A; Bader, GD; Pharoah, PDP; Couch, FJ; Easton, DF; Kraft, P; Chenevix-Trench, G; García-Closas, M; Schmidt, MK; Antoniou, AC; Simard, J (2017-10-23)
    Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease. We conducted a GWAS using 21,468 ER-negative ...
  • Mutations in Epigenetic Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability. 

    Tatton-Brown, K; Loveday, C; Yost, S; Clarke, M; Ramsay, E; Zachariou, A; Elliott, A; Wylie, H; Ardissone, A; Rittinger, O; Stewart, F; Temple, IK; Cole, T; Childhood Overgrowth Collaboration; Mahamdallie, S; Seal, S; Ruark, E; Rahman, N (2017-05-04)
    To explore the genetic architecture of human overgrowth syndromes and human growth control, we performed experimental and bioinformatic analyses of 710 individuals with overgrowth (height and/or head circumference ≥+2 SD) ...
  • Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN. 

    Fowler, A; Mahamdallie, S; Ruark, E; Seal, S; Ramsay, E; Clarke, M; Uddin, I; Wylie, H; Strydom, A; Lunter, G; Rahman, N (2016-11-25)
    Background: Targeted next generation sequencing (NGS) panels are increasingly being used in clinical genomics to increase capacity, throughput and affordability of gene testing. Identifying whole exon deletions or duplications ...
  • Biallelic TRIP13 mutations predispose to Wilms tumor and chromosome missegregation. 

    Yost, S; de Wolf, B; Hanks, S; Zachariou, A; Marcozzi, C; Clarke, M; de Voer, R; Etemad, B; Uijttewaal, E; Ramsay, E; Wylie, H; Elliott, A; Picton, S; Smith, A; Smithson, S; Seal, S; Ruark, E; Houge, G; Pines, J; Kops, GJPL; Rahman, N (2017-07)
    Through exome sequencing, we identified six individuals with biallelic loss-of-function mutations in TRIP13. All six developed Wilms tumor. Constitutional mosaic aneuploidies, microcephaly, developmental delay and seizures, ...
  • OpEx - a validated, automated pipeline optimised for clinical exome sequence analysis. 

    Ruark, E; Münz, M; Clarke, M; Renwick, A; Ramsay, E; Elliott, A; Seal, S; Lunter, G; Rahman, N (2016-01)
    We present an easy-to-use, open-source Optimised Exome analysis tool, OpEx (http://icr.ac.uk/opex) that accurately detects small-scale variation, including indels, to clinical standards. We evaluated OpEx performance with ...
  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk. 

    Michailidou, K; Hall, P; Gonzalez-Neira, A; Ghoussaini, M; Dennis, J; Milne, RL; Schmidt, MK; Chang-Claude, J; Bojesen, SE; Bolla, MK; Wang, Q; Dicks, E; Lee, A; Turnbull, C; Rahman, N; Fletcher, O; Peto, J; Gibson, L; Dos Santos Silva, I; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Czene, K; Irwanto, A; Liu, J; Waisfisz, Q; Meijers-Heijboer, H; Adank, M; van der Luijt, RB; Hein, R; Dahmen, N; Beckman, L; Meindl, A; Schmutzler, RK; Müller-Myhsok, B; Lichtner, P; Hopper, JL; Southey, MC; Makalic, E; Schmidt, DF; Uitterlinden, AG; Hofman, A; Hunter, DJ; Chanock, SJ; Vincent, D; Bacot, F; Tessier, DC; Canisius, S; Wessels, LF; Haiman, CA; Shah, M; Luben, R; Brown, J; Luccarini, C; Schoof, N; Humphreys, K; Li, J; Nordestgaard, BG; Nielsen, SF; Flyger, H; Couch, FJ; Wang, X; Vachon, C; Stevens, KN; Lambrechts, D; Moisse, M; Paridaens, R; Christiaens, MR; Rudolph, A; Nickels, S; Flesch-Janys, D; Johnson, N; Aitken, Z; Aaltonen, K; Heikkinen, T; Broeks, A; Veer, LJ; van der Schoot, CE; Guénel, P; Truong, T; Laurent-Puig, P; Menegaux, F; Marme, F; Schneeweiss, A; Sohn, C; Burwinkel, B; Zamora, MP; Perez, JI; Pita, G; Alonso, MR; Cox, A; Brock, IW; Cross, SS; Reed, MW; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Henderson, BE; Schumacher, F; Le Marchand, L; Andrulis, IL; Knight, JA; Glendon, G; Mulligan, AM; Lindblom, A; Margolin, S; Hooning, MJ; Hollestelle, A; van den Ouweland, AM; Jager, A; Bui, QM; Stone, J; Dite, GS; Apicella, C; Tsimiklis, H; Giles, GG; Severi, G; Baglietto, L; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Müller, H; Arndt, V; Stegmaier, C; Swerdlow, A; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Lissowska, J; Brinton, L; Goldberg, MS; Labrèche, F; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Hamann, U; Brüning, T; Radice, P; Peterlongo, P; Manoukian, S; Bonanni, B; Devilee, P; Tollenaar, RA; Seynaeve, C; van Asperen, CJ; Jakubowska, A; Lubinski, J; Jaworska, K; Durda, K; Mannermaa, A; Kataja, V; Kosma, VM; Hartikainen, JM; Bogdanova, NV; Antonenkova, NN; Dörk, T; Kristensen, VN; Anton-Culver, H; Slager, S; Toland, AE; Edge, S; Fostira, F; Kang, D; Yoo, KY; Noh, DY; Matsuo, K; Ito, H; Iwata, H; Sueta, A; Wu, AH; Tseng, CC; Van Den Berg, D; Stram, DO; Shu, XO; Lu, W; Gao, YT; Cai, H; Teo, SH; Yip, CH; Phuah, SY; Cornes, BK; Hartman, M; Miao, H; Lim, WY; Sng, JH; Muir, K; Lophatananon, A; Stewart-Brown, S; Siriwanarangsan, P; Shen, CY; Hsiung, CN; Wu, PE; Ding, SL; Sangrajrang, S; Gaborieau, V; Brennan, P; McKay, J; Blot, WJ; Signorello, LB; Cai, Q; Zheng, W; Deming-Halverson, S; Shrubsole, M; Long, J; Simard, J; Garcia-Closas, M; Pharoah, PD; Chenevix-Trench, G; Dunning, AM; Benitez, J; Easton, DF (2013-04)
    Breast cancer is the most common cancer among women. Common variants at 27 loci have been identified as associated with susceptibility to breast cancer, and these account for ∼9% of the familial risk of the disease. We ...
  • Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance 

    Martin, L; Ribas, R; Simigdala, N; Schuster, E; Pancholi, S; Tenet, T; Gallery, P; Buluwela, L; Harrow, A; Thornhill, A; Nikitorowicz-Buniak, J; Bhamra, A; Turgeon, M; Poulogiannis, G; Gao, Q; Martins, V; Hills, M; Garcia-Murillas, I; Fribbens, C; Patani, N; Sikora, M; Turner, N; Zwart, W; Oesterreich, S; Carroll, J; Ali, S; Dowsett, M
  • Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. 

    Nikkilä, J; Kumar, R; Campbell, J; Brandsma, I; Pemberton, HN; Wallberg, F; Nagy, K; Scheer, I; Vertessy, BG; Serebrenik, AA; Monni, V; Harris, RS; Pettitt, SJ; Ashworth, A; Lord, CJ (2017-06-27)
    BACKGROUND: Elevated APOBEC3B expression in tumours correlates with a kataegic pattern of localised hypermutation. We assessed the cellular phenotypes associated with high-level APOBEC3B expression and the influence of p53 ...
  • Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response Targeted Therapies in Breast Cancer 

    Naidoo, K; Wai, P; Maguire, S; Daley, F; Haider, S; Kriplani, D; Campbell, J; Mirza, H; Grigoriadis, A; Tutt, A; Moseley, P; Abdel-Fatah, T; Chan, S; Madhusudan, S; Rhaka, E; Ellis, I; Lord, C; Yuan, Y; Green, A; Natrajan, R
  • ATR is a therapeutic target in synovial sarcoma. 

    Jones, SE; Fleuren, EDG; Frankum, J; Konde, A; Williamson, CT; Krastev, DB; Pemberton, HN; Campbell, J; Gulati, A; Elliott, R; Menon, M; Selfe, JL; Brough, R; Pettitt, SJ; Niedzwiedz, W; van der Graaf, WTA; Shipley, J; Ashworth, A; Lord, CJ (2017-10-16)
    Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterised by expression of SS18-SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we ...
  • The receptor protein tyrosine phosphatase PTPRB negatively regulates FGF2-dependent branching morphogenesis. 

    Soady, KJ; Tornillo, G; Kendrick, H; Meniel, V; Olijnyk-Dallis, D; Morris, JS; Stein, T; Gusterson, BA; Isacke, CM; Smalley, MJ (2017-10-15)
    PTPRB is a transmembrane protein tyrosine phosphatase known to regulate blood vessel remodelling and angiogenesis. Here, we demonstrate that PTPRB negatively regulates branching morphogenesis in the mouse mammary epithelium. ...
  • Genome-wide homozygosity signature and risk of Hodgkin lymphoma. 

    Sud, A; Cooke, R; Swerdlow, AJ; Houlston, RS (2015-01)
    Recent studies have reported that regions of homozygosity (ROH) in the genome are detectable in outbred populations and can be associated with an increased risk of malignancy. To examine whether homozygosity is associated ...
  • Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience. 

    Okines, A; Irfan, T; Khabra, K; Smith, I; O'Brien, M; Parton, M; Noble, J; Stanway, S; Somaiah, N; Ring, A; Johnston, S; Turner, N (2017-08-22)
    Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that does not cross an intact blood-brain barrier. In the EMILIA trial of T-DM1 vs capecitabine/lapatinib for HER2 positive advanced breast cancer, all patients ...
  • Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer. 

    Dodson, A; Okonji, D; Assersohn, L; Rigg, A; Sheri, A; Turner, N; Smith, I; Parton, M; Dowsett, M (2017-11-11)
    PURPOSE: Oncotype DX, a gene expression assay widely employed to aid decision making on adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) breast cancer, produces a recurrence score (RS) ...
  • Treating cancer with selective CDK4/6 inhibitors. 

    O'Leary, B; Finn, RS; Turner, NC
    Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological ...
  • Treating cancer with selective CDK4/6 inhibitors. 

    O'Leary, B; Finn, RS; Turner, NC (2016-07)
    Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological ...
  • Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. 

    Dréan, A; Williamson, CT; Brough, R; Brandsma, I; Menon, M; Konde, A; Garcia-Murillas, I; Pemberton, HN; Frankum, J; Rafiq, R; Badham, N; Campbell, J; Gulati, A; Turner, NC; Pettitt, SJ; Ashworth, A; Lord, CJ (2017-09)
    Although PARP inhibitors target BRCA1- or BRCA2-mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or "revertant" mutations in BRCA1 or BRCA2 ...
  • Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. 

    Asghar, US; Barr, AR; Cutts, R; Beaney, M; Babina, I; Sampath, D; Giltnane, J; Lacap, JA; Crocker, L; Young, A; Pearson, A; Herrera-Abreu, MT; Bakal, C; Turner, NC (2017-09-15)
    Purpose: Triple-negative breast cancer (TNBC) is a heterogeneous subgroup of breast cancer that is associated with a poor prognosis. We evaluated the activity of CDK4/6 inhibitors across the TNBC subtypes and investigated ...

View more